Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:EU EMA/698382/2021 - Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol 2021 Appendix I: Difference between revisions

From GxPlex

Jump to: navigation, search
m 1 revision imported
imported>GxPlexBot
Import from GxPlex Excel
Line 4: Line 4:
|RefDocPart=Appendix I
|RefDocPart=Appendix I
|RefLanguage=EN
|RefLanguage=EN
|RefTagsEN=
|RefTags=TAG-00049-Ser-Ver ++ TAG-00327-Exa-spi
|RefTagsOriginal=
|RefModule=4
|RefTagsFR=
|RefUnit=4.1.4
}}
}}


Line 14: Line 14:
|-
|-
! colspan="2" class="gplx-infobox-header" | Reference Details
! colspan="2" class="gplx-infobox-header" | Reference Details
|-
! Module
| Module 4 — Unit 4.1.4
|-
|-
! Scope
! Scope
Line 30: Line 33:
|  
|  
|-
|-
! Tags (EN)
! Tags
|  
| [[Glossary:TAG-00049-Ser-Ver|Serious breach]], [[Glossary:TAG-00327-Exa-spi|Examples]]
|-
! Tags (original language)
|
|-
! Tags (FR)
|  
|-
|-
! Comment
! Comment

Revision as of 17:29, 15 July 2026



Document information
Reference EU EMA/698382/2021

- Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol 2021

Validity area EU
Scope(s) G
Document name EMA/698382/2021

- Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

Version / Revision 2021
Status Current
Document type Official guideline
Language(s) EN
Description EMA/698382/2021

Quality and Safety of Medicines Department Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 4 — Unit 4.1.4
Scope G
Document part Appendix I
Language EN
Original entry by Florian Adragna
Contributors
Tags Serious breach, Examples
Comment Examples of serious breaches

Content

Appendix I – Examples of serious breaches